JP2000514453A5 - - Google Patents

Download PDF

Info

Publication number
JP2000514453A5
JP2000514453A5 JP1998505806A JP50580698A JP2000514453A5 JP 2000514453 A5 JP2000514453 A5 JP 2000514453A5 JP 1998505806 A JP1998505806 A JP 1998505806A JP 50580698 A JP50580698 A JP 50580698A JP 2000514453 A5 JP2000514453 A5 JP 2000514453A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP1998505806A
Other languages
English (en)
Japanese (ja)
Other versions
JP4368421B2 (ja
JP2000514453A (ja
Filing date
Publication date
Priority claimed from IL11883696A external-priority patent/IL118836A/xx
Application filed filed Critical
Publication of JP2000514453A publication Critical patent/JP2000514453A/ja
Publication of JP2000514453A5 publication Critical patent/JP2000514453A5/ja
Application granted granted Critical
Publication of JP4368421B2 publication Critical patent/JP4368421B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP50580698A 1996-07-11 1997-06-20 Ｓ―（―）―ｎ―プロパルギル―１―アミノインダンを含む医薬組成物 Expired - Lifetime JP4368421B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL11883696A IL118836A (en) 1996-07-11 1996-07-11 Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
IL118836 1996-07-11
PCT/IL1997/000205 WO1998002152A1 (en) 1996-07-11 1997-06-20 Pharmaceutical compositions comprising s-(-)-n-propargyl-1-amino indan

Publications (3)

Publication Number Publication Date
JP2000514453A JP2000514453A (ja) 2000-10-31
JP2000514453A5 true JP2000514453A5 (Direct) 2005-03-10
JP4368421B2 JP4368421B2 (ja) 2009-11-18

Family

ID=11069065

Family Applications (1)

Application Number Title Priority Date Filing Date
JP50580698A Expired - Lifetime JP4368421B2 (ja) 1996-07-11 1997-06-20 Ｓ―（―）―ｎ―プロパルギル―１―アミノインダンを含む医薬組成物

Country Status (12)

Country Link
US (1) US6277886B1 (Direct)
EP (1) EP0929298B1 (Direct)
JP (1) JP4368421B2 (Direct)
CN (1) CN1149985C (Direct)
AT (1) ATE328590T1 (Direct)
AU (1) AU3188097A (Direct)
CA (1) CA2260037C (Direct)
DE (1) DE69736066T2 (Direct)
HU (1) HU226961B1 (Direct)
IL (1) IL118836A (Direct)
NO (1) NO326052B1 (Direct)
WO (1) WO1998002152A1 (Direct)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744500A (en) * 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
IL118836A (en) 1996-07-11 2001-01-11 Teva Pharma Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
EP1372664A1 (en) 2001-03-01 2004-01-02 Hollis-Eden Pharmaceuticals Inc. Use of certain steroids for treatment of blood cell deficiencies
EP2298315A1 (en) 2002-08-28 2011-03-23 Harbor BioSciences, Inc. Therapeutic treatment methods
WO2004041151A2 (en) * 2002-11-07 2004-05-21 Technion Research And Development Foundation Ltd. Neuroprotective iron chelators and pharmaceutical compositions comprising them
PT1567152E (pt) 2002-11-15 2013-10-03 Teva Pharma Uso de rasagilina com riluzol para tratar a esclerose lateral amiotrófica
EP2433626B1 (en) 2003-11-25 2015-11-04 Technion Research & Development Foundation Ltd. Compositions and methods for treatment of cardiovascular disorders and diseases
US8097608B2 (en) * 2003-11-25 2012-01-17 Technion Research And Development Foundation Ltd. Methods for treatment of cardiovascular disorders and diseases
JP2005232148A (ja) * 2004-02-03 2005-09-02 Technion Research & Development Foundation Ltd 神経保護剤としてプロパルギルアミンの使用
CA2574925A1 (en) * 2004-07-26 2006-02-09 Teva Pharmaceutical Industries Ltd. Pharmaceutical dosage forms including rasagiline
US20060025446A1 (en) * 2004-07-27 2006-02-02 Jeffrey Sterling Propargyl nitroxides and indanyl nitroxides and their use for the treatment of neurologic diseases and disorders
EP2471536A1 (en) 2004-09-29 2012-07-04 Harbor BioSciences, Inc. Steroid analogs and characterization and treatment methods
ES2420404T3 (es) * 2005-02-17 2013-08-23 Teva Pharmaceutical Industries Ltd. Terapia de combinación con acetato de glatiramero y rasagilina para el tratamiento de esclerosis múltiple
KR20170023211A (ko) 2005-02-23 2017-03-02 테바 파마슈티컬 인더스트리즈 리미티드 함량 균일성이 개선된 라사길린 제형
US8263655B2 (en) 2005-10-06 2012-09-11 Technion Research And Development Foundation Ltd Methods for treatment of renal failure
CN101622225B (zh) * 2005-11-17 2015-04-15 泰华制药工业有限公司 炔丙基氨基茚分离方法
US7572834B1 (en) 2005-12-06 2009-08-11 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations and processes for their preparation
ES2632638T3 (es) 2005-12-09 2017-09-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Ladostigilo de baja dosis para el tratamiento de la deficiencia cognitiva
ES2551481T3 (es) 2006-02-21 2015-11-19 Teva Pharmaceutical Industries, Ltd. Uso de rasagilina para el tratamiento de atrofia multisistémica
TW200744576A (en) 2006-02-24 2007-12-16 Teva Pharma Propargylated aminoindans, processes for preparation, and uses thereof
NZ571591A (en) 2006-04-03 2011-09-30 Teva Pharma Use of rasagiline for the treatment of restless legs syndrome
EP1892233A1 (de) * 2006-08-18 2008-02-27 Ratiopharm GmbH Neue Salze des Wirkstoffs Rasagilin
HRP20110980T1 (hr) * 2006-12-14 2012-02-29 Teva Pharmaceutical Industries Ltd. Kristalna kruta rasagilinska baza
WO2008076315A1 (en) * 2006-12-14 2008-06-26 Teva Pharmaceutical Industries, Ltd. Tannate salt of rasagiline
EP1987816A1 (de) * 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
US20090062400A1 (en) * 2007-09-05 2009-03-05 Laurence Oron Method of treating glaucoma using rasagiline
US8188149B2 (en) * 2007-09-17 2012-05-29 Teva Pharmaceutical Industries, Ltd. Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss
NZ586025A (en) * 2008-01-11 2012-08-31 Teva Pharma Rasagiline mesylate tablet coated with a composisiton comprising methacrylic acid - ethyl acrylate copolymer and triethyl citrate
WO2009122351A2 (en) * 2008-04-01 2009-10-08 Kangwon National University Anti-parkinsonian compounds mppe
WO2009151594A1 (en) * 2008-06-10 2009-12-17 Teva Pharmaceutical Industries, Ltd. Rasagiline soft gelatin capsules
CA2727022A1 (en) * 2008-06-13 2009-12-17 Teva Pharmaceutical Industries Ltd. Rasagiline for parkinson's disease modification
EP2299993A4 (en) * 2008-06-19 2014-08-20 Teva Pharma PROCESS FOR PURIFYING THE BASE OF RASAGILINE
JP2011524907A (ja) 2008-06-19 2011-09-08 テバ ファーマシューティカル インダストリーズ リミティド 固体ラサギリン塩基を調製および乾燥する方法
US20100189788A1 (en) * 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline base formulation
DK2451771T3 (da) 2009-07-09 2014-09-08 Ratiopharm Gmbh Salte af rasagilin og farmaceutiske fremstillingsmåder heraf
RU2607595C2 (ru) 2010-02-03 2017-01-10 Фарма Ту Б Лтд. Составы разагилина с пролонгированным высвобождением и их применение
CA2806740A1 (en) 2010-07-27 2012-02-02 Teva Pharmaceutical Industries Ltd. Use of rasagiline for the treatment of olfactory dysfunction
US8691872B2 (en) 2010-07-27 2014-04-08 Teva Pharmaceutical Industries Ltd. Dispersions of rasagiline citrate
JP2014534196A (ja) 2011-10-10 2014-12-18 テバ ファーマシューティカル インダストリーズ リミティド Ｒ（＋）−ｎ−ホルミル−プロパルギル−アミノインダン
EP2766004A4 (en) 2011-10-10 2015-04-22 Teva Pharma R (+) - N-methyl-propargyl-aminoindan
BR112015003451A2 (pt) 2012-08-17 2017-07-04 Teva Pharma formulação parentérica de rasagilina
CN104177611A (zh) * 2013-05-27 2014-12-03 韩文毅 一种非线性的聚合物及其制备和用途
CN104177610A (zh) * 2013-05-27 2014-12-03 韩文毅 一种非线性的聚合物及其制备和用途
CN111333517A (zh) * 2018-12-19 2020-06-26 上海奥博生物医药技术有限公司 一种制备雷沙吉兰的改进方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1187017A (en) * 1966-07-16 1970-04-08 Aspro Nicholas Ltd Substituted 1-Amino Indanes and Tetrahydronaphthalens
US5744500A (en) * 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
IL92952A (en) * 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
IL112819A (en) * 1991-10-16 2001-11-25 Teva Pharma Fluorinated 1-aminoindan compounds and a process for their preparation
IL111240A (en) * 1993-10-18 2001-10-31 Teva Pharma Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them
JP4782252B2 (ja) * 1994-01-10 2011-09-28 テバ ファーマシューティカル インダストリーズ リミテッド １−アミノインダン及びこれらの組成物
IL115357A (en) * 1995-09-20 2000-01-31 Teva Pharma Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols
IL118836A (en) 1996-07-11 2001-01-11 Teva Pharma Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan

Similar Documents

Publication Publication Date Title
JP2000502280A5 (Direct)
JP2001509322A5 (Direct)
JP2000501018A5 (Direct)
JP2000500076A5 (Direct)
JP2001503929A5 (Direct)
JP2000501324A5 (Direct)
JP2000500055A5 (Direct)
JP2000500026A5 (Direct)
JP2000502472A5 (Direct)
JP2000501338A5 (Direct)
JP2001503324A5 (Direct)
JP2000500874A5 (Direct)
JP2001507069A5 (Direct)
JP2000502425A5 (Direct)
JP2000502485A5 (Direct)
JP2000502568A5 (Direct)
JP2000500912A5 (Direct)
JP2000502570A5 (Direct)
JP2000501876A5 (Direct)
JP2001500199A5 (Direct)
JP2000501229A5 (Direct)
JP2000500857A5 (Direct)
JP2000502316A5 (Direct)
JP2000502714A5 (Direct)
JP2000510736A5 (Direct)